To date， there is no licensed vaccine available to prevent respiratory syncytial virus (RSV) infection. The valuable pre-fusion conformation of the fusion protein (pre-F) is prone to lose high neutralizing antigenic sites. The goals of this study were to stabilize pre-F protein by fixatives and try to find the possibility of developing an inactivated RSV vaccine.

antigenic sites，fixatives，formaldehyde，fusion protein，pre-fusion conformation，protection，pulmonary inflammation，respiratory syncytial virus，stabiliza